The Promise of Low Dose Naltrexone Therapy
Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders
In stock (can be backordered)
About the Book
Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn’s disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers.
About the Author(s)
Elaine A. Moore has worked in hospital laboratories for more than 30 years, primarily in immunohematology and toxicology. She is a freelance medical writer and laboratory consultant. For more information, visit her website at www.elaine-moore.com. She lives in Sedalia, Colorado.
Samantha Wilkinson is a patient advocate for multiple sclerosis and LDN. Through her website www.ldners.org she educates patients about current LDN research. She lives in Edmonds, Washington.
Elaine A. Moore and Samantha Wilkinson
Format: softcover (6 x 9)
Bibliographic Info: 21 photos, glossary, appendix, notes, bibliography, index
Copyright Date: 2009
Series: McFarland Health Topics
Table of Contents
Foreword by Yash Pal Agrawal, M.D., Ph.D. 1
1. The War on Drugs—A History of Naltrexone 11
2. LDN in Autoimmune Diseases 29
3. LDN in Multiple Sclerosis 45
4. LDN in Neurodegenerative Disorders 61
5. LDN in Cancer 78
6. LDN in Autism Spectrum Disorders 95
7. LDN in Wound Healing and Infections 102
8. The Immune System and LDN in HIV/AIDS 108
9. The LDN Experience: A Patient’s Guide to LDN 126
10. The Potential Benefits and Future of LDN 148
Chapter Notes 159
Appendix: Clinical Trials of LDN and Related Compounds 179
Book Reviews & Awards
“fascinating…very well researched…is a convincing and compelling medical textbook”—Suite101.com.